NCT06861088: An ongoing trial by Quercis Pharma AG
This trial is ongoing. It must report results 2 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06861088 |
|---|---|
| Title | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Kinisoquin on Thromboembolic Events in Patients With Metastatic Pancreatic Cancer (CATIQ P3) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 31, 2025 |
| Completion date | Oct. 31, 2027 |
| Required reporting date | Oct. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |